yahoo_financeOriginal article
Bristol-Myers Squibb's Pulmonary Fibrosis Treatment Still Viable Despite Recent Mixed Phase 3 Results, UBS Says
Phase 3MixedBristol-Myers Squibb pulmonary fibrosis treatmentNeutral
AI Analysis
Summary
UBS says Bristol-Myers Squibb's pulmonary fibrosis treatment remains viable despite recent mixed Phase 3 results.
Clinical Trial Data
Phase
Phase 3
Outcome Details
Recent Phase 3 results were mixed; UBS says the treatment is still viable
Importance:5/10
Sentiment:
0.10
pulmonary fibrosisPhase 3analyst commentarymixed results
Related Companies
Read the original article
Published by yahoo_finance on October 15, 2026 5:11 PM